events
05 July 2022
Jean De Gunzburg speaker at the 8th Annual Microbiome Connect Europe 2022 on July 6 at 11.30am CET
Jean De Gunzburg will attend the 8th Annual Microbiome Connect: Europe 2022 on July 6-7 2022 and participate as a…
A new article published in August together with our academic collaborators from University of Paris Diderot (Antimicrob Agents Chemother; 2013 Aug 19), studies the effectiveness of oral DAV131 (a form of DAV132 optimized for rodents) in preventing colonization of a Cefotaxim resistant Klebsiella pneumonia strain (PUG-2) in mice when used in conjunction with Cefotaxim (CTX). Grall’s study shows that DAV131 helps to combat the excess antibiotics excreted into the intestinal tract and minimalize the disruption to the indigenous microflora, which might in turn reduce colonization by resistant strains of bacteria during antibiotic treatments.